Research Study

Treatment-free Remission Accomplished With Dasatinib in Patients With CML
Principal Investigator 
Donna Forrest

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
Leukemia
ClinicalTrials.gov# 
NCT02268370
Status 
Recruiting
Study Start/End 
Sep 18, 2015 to Jun 28, 2017
Locations 
Vancouver General Hospital
Name/Title 
Cindy Manchulenko, Research Nurse
Phone 
604-875-4111 ext.67227
Purpose of Study 

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced.

This research is being done because dasatinib has been shown to achieve a greater response in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately 300 times more potent than imatinib, and it is possible that a greater response can be achieved by dasatinib than by imatinib.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.